Loading
A phase 2/3 trial of Tislelizumab and Cisplatin in oesophageal cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) is a phase 2/3 interventional study registered as NCT07554456 by Sichuan Baili Pharmaceutical Co., Ltd., with 90 participants planned, started 2026-06-09 and due to reach its primary completion in 2028-12. Interventions recorded: BL-B01D1, Tislelizumab, 5-Fluorouracil, Cisplatin and Paclitaxel.
Shares Oesophageal squamous cell carcinoma, Tislelizumab, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin, Immune checkpoint inhibitors and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin, Immune checkpoint inhibitors and the tag pipeline.
Shares Tislelizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Tislelizumab, Oesophageal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Immune checkpoint inhibitors and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer and the tag pipeline.